<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01871506</url>
  </required_header>
  <id_info>
    <org_study_id>2013P001036</org_study_id>
    <secondary_id>1R01CA166147-01A1</secondary_id>
    <nct_id>NCT01871506</nct_id>
  </id_info>
  <brief_title>Integrating Tobacco Treatment Into Cancer Care: A Randomized Controlled Comparative Effectiveness Trial</brief_title>
  <official_title>Integrating Tobacco Treatment Into Cancer Care: A Randomized Controlled Comparative Effectiveness Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      There are currently over 11 million cancer survivors in the U.S. and survival rates are
      increasing. Unfortunately, 10-30% of cancer patients are current smokers at the time of
      diagnosis, and many of these patients have elevated socioeconomic, medical, and psychosocial
      vulnerabilities. Documented risks associated with continued smoking following cancer
      diagnosis include decreased survival time; increased complications from surgery, radiation,
      and chemotherapy; and increased risk of second primary tumors. U.S. Department of Health &amp;
      Human Services Public Health Service evidence-based tobacco treatment guidelines exist but
      have not been integrated into the cancer setting. This is a tremendous missed opportunity to
      address a modifiable risk factor. In recognition of this treatment gap, the National Cancer
      Institute (NCI) sponsored a conference in 2009 to address how to increase the readiness and
      capacity for delivery of tobacco treatment in Cancer Centers. The American Society of
      Clinical Oncology (ASCO) recommends identification, advice, and counseling of all smokers by
      their second oncology visit as a core quality indicator; however, currently only half of
      patients report being asked about tobacco use.

      Specific Aim: To conduct a randomized controlled comparative effectiveness trial of two
      strategies to promote smoking cessation in suspected or newly diagnosed cancer patients.

      Study Design: A multi-site randomized controlled comparative effectiveness trial will enroll
      295 current smokers with suspected or newly diagnosed melanoma, lymphoma, thoracic, breast,
      genitourinary, gastrointestinal, head and neck, or gynecologic cancer. Participants will be
      randomly assigned to receive Intensive Counseling (IC) or &quot;Standard Care&quot; (SC). Both groups
      will receive an initial motivational counseling session and 3 weekly follow-up counseling
      sessions with a tobacco treatment counselor, conducted in-person or by telephone. The IC arm
      has the option to also receive:

        -  Smoking Cessation Medication: Up to a 12-week supply of FDA approved smoking cessation
           medication (Varenicline, bupropion, or combination NRT) at no cost to the participant.

        -  Extended Counseling: An additional 4 biweekly and 3 monthly proactive counseling
           sessions with a tobacco treatment counselor (total of 11 counseling contacts).

      All participants will complete 1 baseline and 2 follow-up surveys, at 3 and 6 months.
      Self-reported abstinence will be biochemically confirmed at 3 and 6 months.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Specific Aims

      Aim 1: To compare the effectiveness of two tobacco treatments that are integrated into cancer
      care in producing tobacco abstinence at 6 months.

      Aim 2: To explore: a) mechanisms through which treatment promotes abstinence; b)
      subpopulations in which abstinence is promoted; and c) which aspects of treatment promote
      abstinence.

      Aim 3: To compare the incremental cost effectiveness (cost per quit) of two tobacco
      treatments.

      Exploratory Aim: To identify the percentage and associated characteristics of smokers who 1)
      enroll in tobacco treatment and 2) adhere to tobacco treatment.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 2013</start_date>
  <completion_date type="Actual">May 2018</completion_date>
  <primary_completion_date type="Actual">May 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Biochemically Verified 7-day Point Prevalence Tobacco Abstinence at 6 Months</measure>
    <time_frame>6 months</time_frame>
    <description>Number of participants with 7-day point-prevalence tobacco abstinence at 6-month follow-up, assessed by biochemically confirmed saliva cotinine (&lt;15 ng/ml76, 82) or &lt;10 ppm expired air carbon monoxide (CO) for participants concurrently using NRT</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Biochemically Verified 7-day Point Prevalence Tobacco Abstinence at 3 Months</measure>
    <time_frame>3 months</time_frame>
    <description>Number of participants with7 -day point-prevalence tobacco abstinence at 3-month follow-up, assessed by biochemically confirmed saliva cotinine (&lt;15 ng/ml76, 82) or &lt;10 ppm expired air carbon monoxide (CO) for participants concurrently using NRT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Continuous Tobacco Abstinence</measure>
    <time_frame>3 months to 6 months</time_frame>
    <description>Number of Participants with Continuous tobacco abstinence (between quit and follow-up) at 3 &amp; 6 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Sustained Tobacco Abstinence</measure>
    <time_frame>6 months</time_frame>
    <description>Number of Participants with Biochemically confirmed repeated point prevalence abstinence at 3 &amp; 6 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Self-reported 7-day Point Prevalence.</measure>
    <time_frame>6 months</time_frame>
    <description>Number of Participants with Self-reported smoking abstinence of at least 7 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Number of IT Participants Who Used Smoking Cessation Pharmacotherapy</measure>
    <time_frame>Treatment Initiation to 6 month follow-up</time_frame>
    <description>The number of IT participants who used 1) smoking cessation pharmacotherapy (Y/N dispensed) 2) smoking cessation counseling (Y/N), 3) 1-2 4-week refills, 4) took 1-3 monthly booster sessions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Number of IT Participants Who Used Smoking Cessation Counseling</measure>
    <time_frame>Treatment Initiation to 6 Month Follow-up</time_frame>
    <description>The number of intervention participants who used smoking cessation counseling during the study (Y/N)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Number of IT Participants Who Took 1-2 4-week Refills</measure>
    <time_frame>Treatment Initiation to 6 Month Follow-up</time_frame>
    <description>The number of intervention participants who took 1-2 4-week refills of smoking cessation medication</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Number of IT Participants Who Took 1-3 Monthly Booster Sessions</measure>
    <time_frame>Treatment Initiation to 6 Month Follow-up</time_frame>
    <description>The number of IT participants who took 1-3 monthly booster sessions of smoking cessation counseling</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cost-effectiveness</measure>
    <time_frame>6 months</time_frame>
    <description>The cost of the standard of care treatment and the cost of the intensive treatment.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">303</enrollment>
  <condition>Smoking Cessation</condition>
  <arm_group>
    <arm_group_label>Standard Care (SC)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants randomized to &quot;standard care&quot; (SC) will have the option to receive 4 behavioral counseling sessions with a tobacco treatment counselor and medication advice.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intensive Counseling (IC)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants randomized to intensive counseling (IC) will receive the same 4 initial behavioral counseling sessions with a tobacco treatment counselor as participants in the SC arm. IC participants have the option to also receive:
Extended Counseling: An additional 4 biweekly and 3 monthly proactive counseling sessions with a tobacco treatment counselor (total of 11 counseling contacts).
Smoking Cessation Medication: Up to a 12-week supply of FDA approved smoking cessation medication [varenicline, bupropion, or combination NRT (patch + lozenge)] at no cost to the participant.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Standard Care (SC)</intervention_name>
    <description>Initial counseling session: The initial counseling session will last approximately 45 minutes and will be conducted in-person or by phone by a tobacco treatment counselor. The session will be structured in a 5 As format and utilize Motivational Interviewing (MI) techniques.
3 Weekly Follow-up Counseling Sessions: SC Patients will be offered 3 weekly proactive follow-up sessions, concentrated on quitting and staying quit throughout cancer treatment.
Medication advice: The tobacco counselor will advise SC subjects to use smoking cessation medication to assist with their quit. Smoking cessation medication will not be provided by the study free of cost for SC subjects.</description>
    <arm_group_label>Standard Care (SC)</arm_group_label>
    <other_name>&quot;Standard of Care&quot; Treatment</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Intensive Counseling (IC)</intervention_name>
    <description>The IC model includes all components of the SC as well as extended counseling support and up to 90 days of free FDA approved smoking cessation medication.
Extended counseling support: Participants in the IC group will be offered the same initial 4 counseling sessions as the SC group as well as 4 additional proactive biweekly sessions and 3 monthly booster sessions.
Smoking cessation medication: IC participants will be offered a 4-week supply of FDA-approved smoking cessation medication (varenicline, bupropion or nicotine replacement therapy) of their choice, with the option to renew the medication twice for up to 90 days of free medication. Participants are not required to take smoking cessation medication.</description>
    <arm_group_label>Intensive Counseling (IC)</arm_group_label>
    <other_name>Intensive Treatment</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        INCLUSION CRITERIA:

        Adult men and women may participate in this study if he/she meet the following
        requirements:

          1. Current, new* patient at one of our three participating study sites: Massachusetts
             General Hospital (MGH) Cancer Center, Memorial Sloan Kettering Cancer Center (MSKCC),
             or Dana-Farber Cancer Institute (DFCI);

          2. Currently with suspected or newly diagnosed cancer (thoracic, breast, genitourinary,
             gastrointestinal, head and neck, gynecologic, lymphoma, melanoma);

          3. Has smoked a cigarette, even a puff, in the past 30 days;

          4. Is willing to consider trying to quit smoking using counseling and/or smoking
             cessation medication;

          5. Is English or Spanish speaking (MGH); English speaking (MSK; DFCI);

          6. Has regular telephone access.

        [*Patients will be considered &quot;new&quot; and eligible under the following conditions:

          1. if they are attending approximately one of their first 4 visits or are within
             approximately 3 months of the initial visit date with their primary oncologist at the
             Massachusetts General Hospital (MGH) Cancer Center, Memorial Sloan Kettering Cancer
             Center (MSKCC), or Dana-Farber Cancer Institute (DFCI) for suspected or recently
             diagnosed cancer;

          2. if they come to the MGH, MSKCC, or DFCI for a second opinion, the patient opts to
             receive their cancer treatment at any of these institutions;

          3. if they have a past cancer diagnosis, they are currently faced with a local and
             distant recurrence of tumors;

          4. if they have been treated previously for other types of cancer, they are currently
             faced with a new form of cancer.]

        EXCLUSION CRITERIA:

        In an effort to be as inclusive as possible, a patient will be excluded only if he/she:

          1. Is NOT currently receiving or has no intentions to receive care at one of three
             participating cancer treatment centers: Massachusetts General Hospital Cancer Center,
             Memorial Sloan Kettering Cancer Center, or Dana-Farber Cancer Institute (DFCI);

          2. Is currently psychiatrically unstable or otherwise unable to provide informed consent
             as determined by study investigators or oncology clinician;

          3. Is not English or Spanish speaking;

          4. Is medically ineligible (as determined by their treating physician);

          5. Has insufficient comprehension/literacy.

        ADDITIONAL INFORMATION:

        Participant inclusion/exclusion is not based on use of smoking cessation medication --
        he/she may decide not to use any smoking cessation medication and still participate in the
        study. Patients deemed ineligible will be referred to the state quit line.

        Patients interested in participating in the study should contact the appropriate contact
        person, based on whether they are a current patient at the MGH, MSKCC, or DFCI.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elyse R Park, Ph.D., MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jamie S. Ostroff, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>June 4, 2013</study_first_submitted>
  <study_first_submitted_qc>June 4, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 6, 2013</study_first_posted>
  <results_first_submitted>May 21, 2019</results_first_submitted>
  <results_first_submitted_qc>August 13, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">August 28, 2019</results_first_posted>
  <last_update_submitted>August 13, 2019</last_update_submitted>
  <last_update_submitted_qc>August 13, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 28, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Elyse Park, PhD</investigator_full_name>
    <investigator_title>Associate Professor of Psychiatry, Harvard Medical School</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>May 10, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/06/NCT01871506/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Between 11/25/2013 and 7/1/2017 4709 patients were screened for eligibility. 2659 were eligible based on screen criteria; 1808 did not complete the screen. Of the 851 who were approached to complete the screen, 405 were ineligible, 303 enrolled and were randomized, and 143 refused (84 refused consent and 59 did not complete the baseline survey)</recruitment_details>
      <pre_assignment_details>Of the 446 eligible for the study, 303 were randomized, 84 were eligible but refused consent (top 3 reasons: too upset, did not need help, had no time) and 59 were eligible but were not randomized because they did not complete a baseline survey.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Standard Treatment (ST)</title>
          <description>Participants randomized to &quot;standard treatment&quot; will have the option to receive 4 behavioral counseling sessions with a tobacco treatment counselor and medication advice.
Standard Treatment (ST): (1) Initial counseling session: The initial counseling session will last approximately 45 minutes and will be conducted in-person or by phone by a tobacco treatment counselor. The session will be structured in a 5 As format and utilize Motivational Interviewing (MI) techniques.
(2) 3 Weekly Follow-up Counseling Sessions: SC Patients will be offered 3 weekly proactive follow-up sessions, concentrated on quitting and staying quit throughout cancer treatment.
(3) Medication advice: The tobacco counselor will advise SC subjects to use smoking cessation medication to assist with their quit. Smoking cessation medication will not be provided by the study free of cost for SC subjects.</description>
        </group>
        <group group_id="P2">
          <title>Intensive Treatment (IT)</title>
          <description>Participants randomized to intensive treatment (IT) will receive the same 4 initial behavioral counseling sessions with a tobacco treatment counselor as participants in the ST arm. IT participants have the option to also receive:
Extended Counseling: An additional 4 biweekly and 3 monthly proactive counseling sessions with a tobacco treatment counselor (total of 11 counseling contacts).
Smoking Cessation Medication: Up to a 12-week supply of FDA approved smoking cessation medication [varenicline, bupropion, or combination NRT (patch + lozenge)] at no cost to the participant.
Intensive Treatment (IT): The IT model includes all components of the ST as well as extended counseling support and up to 90 days of free FDA approved smoking cessation medication.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="150"/>
                <participants group_id="P2" count="153"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="150"/>
                <participants group_id="P2" count="153"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Standard Treatment (ST)</title>
          <description>Participants randomized to &quot;standard treatment&quot; will have the option to receive 4 behavioral counseling sessions with a tobacco treatment counselor and medication advice.
Standard Treatment (ST): (1) Initial counseling session: The initial counseling session will last approximately 45 minutes and will be conducted in-person or by phone by a tobacco treatment counselor. The session will be structured in a 5 As format and utilize Motivational Interviewing (MI) techniques.
(2) 3 Weekly Follow-up Counseling Sessions: ST Patients will be offered 3 weekly proactive follow-up sessions, concentrated on quitting and staying quit throughout cancer treatment.
(3) Medication advice: The tobacco counselor will advise SC subjects to use smoking cessation medication to assist with their quit. Smoking cessation medication will not be provided by the study free of cost for SC subjects.</description>
        </group>
        <group group_id="B2">
          <title>Intensive Treatment (IT)</title>
          <description>Participants randomized to intensive treatment (IT) will receive the same 4 initial behavioral counseling sessions with a tobacco treatment counselor as participants in the SC arm. IC participants have the option to also receive:
Extended Counseling: An additional 4 biweekly and 3 monthly proactive counseling sessions with a tobacco treatment counselor (total of 11 counseling contacts).
Smoking Cessation Medication: Up to a 12-week supply of FDA approved smoking cessation medication [varenicline, bupropion, or combination NRT (patch + lozenge)] at no cost to the participant.
Intensive Counseling: The IT model includes all components of the ST as well as extended counseling support and up to 90 days of free FDA approved smoking cessation medication.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="150"/>
            <count group_id="B2" value="153"/>
            <count group_id="B3" value="303"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58" spread="9.5"/>
                    <measurement group_id="B2" value="58" spread="9.9"/>
                    <measurement group_id="B3" value="58" spread="9.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="83"/>
                    <measurement group_id="B2" value="87"/>
                    <measurement group_id="B3" value="170"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="67"/>
                    <measurement group_id="B2" value="66"/>
                    <measurement group_id="B3" value="133"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="146"/>
                    <measurement group_id="B2" value="146"/>
                    <measurement group_id="B3" value="292"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="31"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="131"/>
                    <measurement group_id="B2" value="134"/>
                    <measurement group_id="B3" value="265"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="150"/>
                    <measurement group_id="B2" value="153"/>
                    <measurement group_id="B3" value="303"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Biochemically Verified 7-day Point Prevalence Tobacco Abstinence at 6 Months</title>
        <description>Number of participants with 7-day point-prevalence tobacco abstinence at 6-month follow-up, assessed by biochemically confirmed saliva cotinine (&lt;15 ng/ml76, 82) or &lt;10 ppm expired air carbon monoxide (CO) for participants concurrently using NRT</description>
        <time_frame>6 months</time_frame>
        <population>Twenty participants were too ill or deceased to complete follow-up assessment. Given the study participant population of cancer patients, our trial was powered accounting for cancer deaths and reporting participants who were alive at follow-up assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Standard Treatment (ST)</title>
            <description>Participants randomized to &quot;standard treatment&quot; (ST) will have the option to receive 4 behavioral counseling sessions with a tobacco treatment counselor and medication advice.
Standard Treatment (ST): (1) Initial counseling session: The initial counseling session will last approximately 45 minutes and will be conducted in-person or by phone by a tobacco treatment counselor. The session will be structured in a 5 As format and utilize Motivational Interviewing (MI) techniques.
(2) 3 Weekly Follow-up Counseling Sessions: SC Patients will be offered 3 weekly proactive follow-up sessions, concentrated on quitting and staying quit throughout cancer treatment.
(3) Medication advice: The tobacco counselor will advise SC subjects to use smoking cessation medication to assist with their quit. Smoking cessation medication will not be provided by the study free of cost for SC subjects.</description>
          </group>
          <group group_id="O2">
            <title>Intensive Treatment (IT)</title>
            <description>Participants randomized to the Intensive Treatment (IT) will receive the same 4 initial behavioral counseling sessions with a tobacco treatment counselor as participants in the SC arm. IT participants have the option to also receive:
Extended Counseling: An additional 4 biweekly and 3 monthly proactive counseling sessions with a tobacco treatment counselor (total of 11 counseling contacts).
Smoking Cessation Medication: Up to a 12-week supply of FDA approved smoking cessation medication [varenicline, bupropion, or combination NRT (patch + lozenge)] at no cost to the participant.
Intensive Counseling (IC): The IC model includes all components of the SC as well as extended counseling support and up to 90 days of free FDA approved smoking cessation medication.
(1) Extended counseling support: Participants in the IC group will be offered the same initial 4 counseling sessions as the SC group as well as 4 additional proactive biweekly sessions and 3 monthly booster sessions.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Biochemically Verified 7-day Point Prevalence Tobacco Abstinence at 6 Months</title>
          <description>Number of participants with 7-day point-prevalence tobacco abstinence at 6-month follow-up, assessed by biochemically confirmed saliva cotinine (&lt;15 ng/ml76, 82) or &lt;10 ppm expired air carbon monoxide (CO) for participants concurrently using NRT</description>
          <population>Twenty participants were too ill or deceased to complete follow-up assessment. Given the study participant population of cancer patients, our trial was powered accounting for cancer deaths and reporting participants who were alive at follow-up assessment.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="135"/>
                <count group_id="O2" value="148"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Biochemically Verified 7-day Point Prevalence Tobacco Abstinence at 3 Months</title>
        <description>Number of participants with7 -day point-prevalence tobacco abstinence at 3-month follow-up, assessed by biochemically confirmed saliva cotinine (&lt;15 ng/ml76, 82) or &lt;10 ppm expired air carbon monoxide (CO) for participants concurrently using NRT</description>
        <time_frame>3 months</time_frame>
        <population>Twenty participants were too ill or deceased to complete follow-up assessment. Given the study participant population of cancer patients, our trial was powered accounting for cancer deaths and reporting participants who were alive at follow-up assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Standard Treatment (ST)</title>
            <description>Participants randomized to ST will have the option to receive 4 behavioral counseling sessions with a tobacco treatment counselor and medication advice.
Standard Care (SC): (1) Initial counseling session: The initial counseling session will last approximately 45 minutes and will be conducted in-person or by phone by a tobacco treatment counselor. The session will be structured in a 5 As format and utilize Motivational Interviewing (MI) techniques.
(2) 3 Weekly Follow-up Counseling Sessions: SC Patients will be offered 3 weekly proactive follow-up sessions, concentrated on quitting and staying quit throughout cancer treatment.
(3) Medication advice: The tobacco counselor will advise SC subjects to use smoking cessation medication to assist with their quit. Smoking cessation medication will not be provided by the study free of cost for SC subjects.</description>
          </group>
          <group group_id="O2">
            <title>Intensive Treatment (IT)</title>
            <description>Participants randomized to IT will receive the same 4 initial behavioral counseling sessions with a tobacco treatment counselor as participants in the SC arm. IC participants have the option to also receive:
Extended Counseling: An additional 4 biweekly and 3 monthly proactive counseling sessions with a tobacco treatment counselor (total of 11 counseling contacts).
Smoking Cessation Medication: Up to a 12-week supply of FDA approved smoking cessation medication [varenicline, bupropion, or combination NRT (patch + lozenge)] at no cost to the participant.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Biochemically Verified 7-day Point Prevalence Tobacco Abstinence at 3 Months</title>
          <description>Number of participants with7 -day point-prevalence tobacco abstinence at 3-month follow-up, assessed by biochemically confirmed saliva cotinine (&lt;15 ng/ml76, 82) or &lt;10 ppm expired air carbon monoxide (CO) for participants concurrently using NRT</description>
          <population>Twenty participants were too ill or deceased to complete follow-up assessment. Given the study participant population of cancer patients, our trial was powered accounting for cancer deaths and reporting participants who were alive at follow-up assessment.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="135"/>
                <count group_id="O2" value="148"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Continuous Tobacco Abstinence</title>
        <description>Number of Participants with Continuous tobacco abstinence (between quit and follow-up) at 3 &amp; 6 months</description>
        <time_frame>3 months to 6 months</time_frame>
        <population>Twenty participants were too ill or deceased to complete follow-up assessment. Given the study participant population of cancer patients, our trial was powered accounting for cancer deaths and reporting participants who were alive at follow-up assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Standard Treatment</title>
            <description>Participants randomized to ST will have the option to receive 4 behavioral counseling sessions with a tobacco treatment counselor and medication advice.
.</description>
          </group>
          <group group_id="O2">
            <title>Intensive Treatment)</title>
            <description>Participants randomized to intensive counseling IT will receive the same 4 initial behavioral counseling sessions with a tobacco treatment counselor as participants in the ST ar,m.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Continuous Tobacco Abstinence</title>
          <description>Number of Participants with Continuous tobacco abstinence (between quit and follow-up) at 3 &amp; 6 months</description>
          <population>Twenty participants were too ill or deceased to complete follow-up assessment. Given the study participant population of cancer patients, our trial was powered accounting for cancer deaths and reporting participants who were alive at follow-up assessment.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="135"/>
                <count group_id="O2" value="148"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Sustained Tobacco Abstinence</title>
        <description>Number of Participants with Biochemically confirmed repeated point prevalence abstinence at 3 &amp; 6 months</description>
        <time_frame>6 months</time_frame>
        <population>Twenty participants were too ill or deceased to complete follow-up assessment. Given the study participant population of cancer patients, our trial was powered accounting for cancer deaths and reporting participants who were alive at follow-up assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Standard Treatment (ST)</title>
            <description>Participants randomized to ST will have the option to receive 4 behavioral counseling sessions with a tobacco treatment counselor and medication advice.
.</description>
          </group>
          <group group_id="O2">
            <title>Intensive Treatment (IT)</title>
            <description>Participants randomized to IT will receive the same 4 initial behavioral counseling sessions with a tobacco treatment counselor as participants in the SC arm. IC participants have the option to also receive:
.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Sustained Tobacco Abstinence</title>
          <description>Number of Participants with Biochemically confirmed repeated point prevalence abstinence at 3 &amp; 6 months</description>
          <population>Twenty participants were too ill or deceased to complete follow-up assessment. Given the study participant population of cancer patients, our trial was powered accounting for cancer deaths and reporting participants who were alive at follow-up assessment.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="135"/>
                <count group_id="O2" value="148"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Self-reported 7-day Point Prevalence.</title>
        <description>Number of Participants with Self-reported smoking abstinence of at least 7 days</description>
        <time_frame>6 months</time_frame>
        <population>Twenty participants were too ill or deceased to complete follow-up assessment. Given the study participant population of cancer patients, our trial was powered accounting for cancer deaths and reporting participants who were alive at follow-up assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Standard Treatment (ST)</title>
            <description>Participants randomized to ST will have the option to receive 4 behavioral counseling sessions with a tobacco treatment counselor and medication advice.
.</description>
          </group>
          <group group_id="O2">
            <title>Intensive Treatment (IT)</title>
            <description>Participants randomized to IT will receive the same 4 initial behavioral counseling sessions with a tobacco treatment counselor as participants in the SC arm. IC participants have the option to also receive:</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Self-reported 7-day Point Prevalence.</title>
          <description>Number of Participants with Self-reported smoking abstinence of at least 7 days</description>
          <population>Twenty participants were too ill or deceased to complete follow-up assessment. Given the study participant population of cancer patients, our trial was powered accounting for cancer deaths and reporting participants who were alive at follow-up assessment.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="135"/>
                <count group_id="O2" value="148"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42"/>
                    <measurement group_id="O2" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Number of IT Participants Who Used Smoking Cessation Pharmacotherapy</title>
        <description>The number of IT participants who used 1) smoking cessation pharmacotherapy (Y/N dispensed) 2) smoking cessation counseling (Y/N), 3) 1-2 4-week refills, 4) took 1-3 monthly booster sessions.</description>
        <time_frame>Treatment Initiation to 6 month follow-up</time_frame>
        <population>Only assessed intensive treatment arm.</population>
        <group_list>
          <group group_id="O1">
            <title>Standard Treatment (ST)</title>
            <description>Participants randomized to ST will have the option to receive 4 behavioral counseling sessions with a tobacco treatment counselor and medication advice.
S.</description>
          </group>
          <group group_id="O2">
            <title>Intensive Treatment (IT)</title>
            <description>Participants randomized to IT will receive the same 4 initial behavioral counseling sessions with a tobacco treatment counselor as participants in the SC arm. IC participants have the option to also receive:
.</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of IT Participants Who Used Smoking Cessation Pharmacotherapy</title>
          <description>The number of IT participants who used 1) smoking cessation pharmacotherapy (Y/N dispensed) 2) smoking cessation counseling (Y/N), 3) 1-2 4-week refills, 4) took 1-3 monthly booster sessions.</description>
          <population>Only assessed intensive treatment arm.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="153"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="122"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Number of IT Participants Who Used Smoking Cessation Counseling</title>
        <description>The number of intervention participants who used smoking cessation counseling during the study (Y/N)</description>
        <time_frame>Treatment Initiation to 6 Month Follow-up</time_frame>
        <population>Only assessed intensive treatment arm</population>
        <group_list>
          <group group_id="O1">
            <title>Standard Treatment (ST)</title>
            <description>Participants randomized to &quot;standard treatment&quot; will have the option to receive 4 behavioral counseling sessions with a tobacco treatment counselor and medication advice.
Standard Treatment (ST): (1) Initial counseling session: The initial counseling session will last approximately 45 minutes and will be conducted in-person or by phone by a tobacco treatment counselor. The session will be structured in a 5 As format and utilize Motivational Interviewing (MI) techniques.
(2) 3 Weekly Follow-up Counseling Sessions: SC Patients will be offered 3 weekly proactive follow-up sessions, concentrated on quitting and staying quit throughout cancer treatment.
(3) Medication advice: The tobacco counselor will advise SC subjects to use smoking cessation medication to assist with their quit. Smoking cessation medication will not be provided by the study free of cost for SC subjects.</description>
          </group>
          <group group_id="O2">
            <title>Intensive Treatment (IT)</title>
            <description>Participants randomized to intensive treatment (IT) will receive the same 4 initial behavioral counseling sessions with a tobacco treatment counselor as participants in the ST arm. IT participants have the option to also receive:
Extended Counseling: An additional 4 biweekly and 3 monthly proactive counseling sessions with a tobacco treatment counselor (total of 11 counseling contacts).
Smoking Cessation Medication: Up to a 12-week supply of FDA approved smoking cessation medication [varenicline, bupropion, or combination NRT (patch + lozenge)] at no cost to the participant.
Intensive Treatment (IT): The IT model includes all components of the ST as well as extended counseling support and up to 90 days of free FDA approved smoking cessation medication.</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of IT Participants Who Used Smoking Cessation Counseling</title>
          <description>The number of intervention participants who used smoking cessation counseling during the study (Y/N)</description>
          <population>Only assessed intensive treatment arm</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="153"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="153"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Number of IT Participants Who Took 1-2 4-week Refills</title>
        <description>The number of intervention participants who took 1-2 4-week refills of smoking cessation medication</description>
        <time_frame>Treatment Initiation to 6 Month Follow-up</time_frame>
        <population>Only assessed intensive treatment arm</population>
        <group_list>
          <group group_id="O1">
            <title>Standard Treatment (ST)</title>
            <description>Participants randomized to &quot;standard treatment&quot; will have the option to receive 4 behavioral counseling sessions with a tobacco treatment counselor and medication advice.
Standard Treatment (ST): (1) Initial counseling session: The initial counseling session will last approximately 45 minutes and will be conducted in-person or by phone by a tobacco treatment counselor. The session will be structured in a 5 As format and utilize Motivational Interviewing (MI) techniques.
(2) 3 Weekly Follow-up Counseling Sessions: ST Patients will be offered 3 weekly proactive follow-up sessions, concentrated on quitting and staying quit throughout cancer treatment.
(3) Medication advice: The tobacco counselor will advise SC subjects to use smoking cessation medication to assist with their quit. Smoking cessation medication will not be provided by the study free of cost for SC subjects.</description>
          </group>
          <group group_id="O2">
            <title>Intensive Treatment (IT)</title>
            <description>Participants randomized to intensive treatment (IT) will receive the same 4 initial behavioral counseling sessions with a tobacco treatment counselor as participants in the SC arm. IC participants have the option to also receive:
Extended Counseling: An additional 4 biweekly and 3 monthly proactive counseling sessions with a tobacco treatment counselor (total of 11 counseling contacts).
Smoking Cessation Medication: Up to a 12-week supply of FDA approved smoking cessation medication [varenicline, bupropion, or combination NRT (patch + lozenge)] at no cost to the participant.
Intensive Counseling: The IT model includes all components of the ST as well as extended counseling support and up to 90 days of free FDA approved smoking cessation medication.</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of IT Participants Who Took 1-2 4-week Refills</title>
          <description>The number of intervention participants who took 1-2 4-week refills of smoking cessation medication</description>
          <population>Only assessed intensive treatment arm</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="153"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Number of IT Participants Who Took 1-3 Monthly Booster Sessions</title>
        <description>The number of IT participants who took 1-3 monthly booster sessions of smoking cessation counseling</description>
        <time_frame>Treatment Initiation to 6 Month Follow-up</time_frame>
        <population>Only assessed intensive treatment arm</population>
        <group_list>
          <group group_id="O1">
            <title>Standard Treatment (ST)</title>
            <description>Participants randomized to &quot;standard treatment&quot; will have the option to receive 4 behavioral counseling sessions with a tobacco treatment counselor and medication advice.
Standard Treatment (ST): (1) Initial counseling session: The initial counseling session will last approximately 45 minutes and will be conducted in-person or by phone by a tobacco treatment counselor. The session will be structured in a 5 As format and utilize Motivational Interviewing (MI) techniques.
(2) 3 Weekly Follow-up Counseling Sessions: ST Patients will be offered 3 weekly proactive follow-up sessions, concentrated on quitting and staying quit throughout cancer treatment.
(3) Medication advice: The tobacco counselor will advise SC subjects to use smoking cessation medication to assist with their quit. Smoking cessation medication will not be provided by the study free of cost for SC subjects.</description>
          </group>
          <group group_id="O2">
            <title>Intensive Treatment (IT)</title>
            <description>Participants randomized to intensive treatment (IT) will receive the same 4 initial behavioral counseling sessions with a tobacco treatment counselor as participants in the SC arm. IC participants have the option to also receive:
Extended Counseling: An additional 4 biweekly and 3 monthly proactive counseling sessions with a tobacco treatment counselor (total of 11 counseling contacts).
Smoking Cessation Medication: Up to a 12-week supply of FDA approved smoking cessation medication [varenicline, bupropion, or combination NRT (patch + lozenge)] at no cost to the participant.
Intensive Counseling: The IT model includes all components of the ST as well as extended counseling support and up to 90 days of free FDA approved smoking cessation medication.</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of IT Participants Who Took 1-3 Monthly Booster Sessions</title>
          <description>The number of IT participants who took 1-3 monthly booster sessions of smoking cessation counseling</description>
          <population>Only assessed intensive treatment arm</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="153"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cost-effectiveness</title>
        <description>The cost of the standard of care treatment and the cost of the intensive treatment.</description>
        <time_frame>6 months</time_frame>
        <population>Cost per quit (in dollars) are shown below.</population>
        <group_list>
          <group group_id="O1">
            <title>Standard Treatment (ST)</title>
            <description>Participants randomized to ST will have the option to receive 4 behavioral counseling sessions with a tobacco treatment counselor and medication advice.
.</description>
          </group>
          <group group_id="O2">
            <title>Intensive Treatment</title>
            <description>Participants randomized to IT will receive the same 4 initial behavioral counseling sessions with a tobacco treatment counselor as participants in the SC arm. IC participants have the option to also receive:
.</description>
          </group>
        </group_list>
        <measure>
          <title>Cost-effectiveness</title>
          <description>The cost of the standard of care treatment and the cost of the intensive treatment.</description>
          <population>Cost per quit (in dollars) are shown below.</population>
          <units>dollars</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="150"/>
                <count group_id="O2" value="153"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="638" lower_limit="570" upper_limit="710"/>
                    <measurement group_id="O2" value="1144" lower_limit="1061" upper_limit="1231"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events for each participant was collected over a 6-month period: from baseline to 6 month follow-up.</time_frame>
      <desc>Adverse events: Any untoward or unfavorable medical occurrence in a human subject including any abnormal sign, symptom, or disease...whether or not associated with the subjects participation in research. *Adverse events that are expected (i.e., documented in the protocol) are not reported to the IRB. More than one adverse event could be reported per participant.</desc>
      <group_list>
        <group group_id="E1">
          <title>Standard Treatment (ST)</title>
          <description>Participants randomized to &quot;standard treatment&quot; (ST) will have the option to receive 4 behavioral counseling sessions with a tobacco treatment counselor and medication advice.
Standard Treatment (ST): (1) Initial counseling session: The initial counseling session will last approximately 45 minutes and will be conducted in-person or by phone by a tobacco treatment counselor. The session will be structured in a 5 As format and utilize Motivational Interviewing (MI) techniques.
(2) 3 Weekly Follow-up Counseling Sessions: SC Patients will be offered 3 weekly proactive follow-up sessions, concentrated on quitting and staying quit throughout cancer treatment.
(3) Medication advice: The tobacco counselor will advise SC subjects to use smoking cessation medication to assist with their quit. Smoking cessation medication will not be provided by the study free of cost for SC subjects.</description>
        </group>
        <group group_id="E2">
          <title>Intensive Treatment (IT)</title>
          <description>Participants randomized to intensive treatment (IT) will receive the same 4 initial behavioral counseling sessions with a tobacco treatment counselor as participants in the SC arm. IT participants have the option to also receive:
Extended Counseling: An additional 4 biweekly and 3 monthly proactive counseling sessions with a tobacco treatment counselor (total of 11 counseling contacts).
Smoking Cessation Medication: Up to a 12-week supply of FDA approved smoking cessation medication [varenicline, bupropion, or combination NRT (patch + lozenge)] at no cost to the participant.
I</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="41" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <description>General nausea, nausea and upset stomach, nausea and vomiting, nausea and increased heart rate related to smoking cessation medication use</description>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="150"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <description>Rash related to smoking cessation medication</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Hiccups</sub_title>
                <description>Hiccups related to use of smoking cessation medication</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>SIADH</sub_title>
                <description>SIADH reaction to smoking cessation medication use</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Bad taste in mouth</sub_title>
                <description>Bad taste in mouth related to smoking cessation medication</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <description>Flatulence related to smoking cessation medication</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Mouth irritation</sub_title>
                <description>Mouth irritation, burning sensation in mouth, tingling sensation on tongue related to smoking cessation medication</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Difficulty sleeping</sub_title>
                <description>Difficulty sleeping related to smoking cessation medication</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="150"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <description>Fatigue or fog-headedness related to smoking cessation medication</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <description>Chest discomfort or palpitations related to smoking cessation medication</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Pain in lower back and leg</sub_title>
                <description>Pain in lower back and leg related to smoking cessation medication</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <description>Headache and headache with diarrhea related to smoking cessation medication</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="150"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Heartburn</sub_title>
                <description>Heartburn related to smoking cessation medication</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Lightheadedness</sub_title>
                <description>Lightheadedness related to smoking cessation medication</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Swollen ankles</sub_title>
                <description>Swollen ankles related to smoking cessation medication</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Vivid dreams</sub_title>
                <description>Vivid dreams related to smoking cessation medication</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="150"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <description>Malaise related to smoking cessation medication</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Shortness of breath</sub_title>
                <description>Shortness of breath related to smoking cessation medication</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Associate Professor</name_or_title>
      <organization>Elyse Park</organization>
      <phone>617-724-6836</phone>
      <email>epark@mgh.harvard.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

